CombinatoRx posts profit in Q4
This article was originally published in Scrip
Executive Summary
CombinatoRx has reported a fourth quarter profit of $25.2 million on lower R&D spending and gains from its acquisition of Neuromed Pharmaceuticals. The US firm's shares closed up by 8% to $1.36 yesterday after swinging from a fourth-quarter loss of $15.2 million the year before.